Зулейхат Алаудиновна Алискандиева
Зулейхат Алаудиновна Алискандиева has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Aleksandr S. Prilutskiy
M. Gorky Donetsk National Medical University
2 shared publications - Andrey Vyacheslavovich Kamaev
Federal State Budgetary Educational Institution of Higher Education First St. Petersburg State Medical University named after Academician I.P. Pavlov of the Ministry of Health of the Russian Federation / Pavlov University
2 shared publications - Elena V. Stezhkina
Federal State Budgetary Educational Institution of Higher Education “Ryazan State Medical University named after Academician I. P. Pavlov” of the Ministry of Health of the Russian Federation
2 shared publications - Ella V. Churyukina
Rostov State Medical University; Kuban State Medical University
2 shared publications - Inna A. Larkova
Federal Research Center of Nutrition and Biotechnology
2 shared publications - Ksenia A. Bocharova
Federal State Autonomous Educational Institution of Higher Education “Belgorod State National Research University
2 shared publications
Latest Publications
- Open Access
- 30 July 2026
- Published by Association of Pediatric Allergologists and Immunologists of Russia in Allergology and Immunology in Paediatrics
- No. 1,p. 6-184
Allergic rhinitis in children — a consensus document of the Association of Pediatric Allergists and Immunologists of Russia
Background. Allergic rhinitis (AR) is the most prevalent allergic disease globally, particularly within the pediatric population. Its high prevalence and substantial impact on quality of life render it a pressing clinical concern. Notable challenges persist in early diagnosis, comprehension of pathogenetic mechanisms, and optimization of therapeutic strategies, especially in young children. Objective. To present a contemporary review and consensus recommendations from the Association of Pediatric Allergists and Immunologists of Russia (APAIR) on the management of pediatric AR, encompassing pathogenetic mechanisms, risk factors, clinical presentation, diagnostic approaches, and therapeutic modalities. Materials and Methods. This work synthesizes current national and international research, including data from meta-analyses and clinical guidelines, alongside original expert contributions from APAIR members. Results. Experts conceptualize AR as a mixed immune-inflammatory disorder involving the classical IgE-dependent pathway (Type I), cellular responses (Type IV), and epithelial dysfunction (Type V). The significance of risk factors, including genetics, microbiome composition, pollutant exposure, and allergen contact, is underscored. Data on the substantial prevalence of AR are presented, highlighting its underdiagnosis in young children and patients with comorbid conditions such as atopic dermatitis and food allergy. A refined, more clinically applicable definition of AR is proposed. Algorithms for stepwise pharmacotherapy are thoroughly detailed, including the evidence-based use of antihistamines as initial therapy for young children and patients with mild AR, intranasal corticosteroids as the cornerstone of treatment, and fixed intranasal combinations for both baseline and on-demand therapy. A personalized approach based on age (0–18 years) and clinical phenotype is emphasized. APAIR experts underscore the role of allergen-specific immunotherapy (AIT) as the only disease-modifying intervention, in contrast to pharmacotherapy, which primarily provides symptomatic control. Conclusion. Timely diagnosis and appropriate, stepwise therapy for AR in children facilitate symptom control and significantly improve patients’ quality of life. Furthermore, the incorporation of AIT can prevent disease progression, including the development of bronchial asthma. This consensus document aims to assist clinicians in making evidence-based clinical decisions.
- 30 July 2026
- Published by Association of Pediatric Allergologists and Immunologists of Russia in Allergology and Immunology in Paediatrics
- No. 1,p. 6-184
Open AccessAllergic rhinitis in children — a consensus document of the Association of Pediatric Allergists and Immunologists of Russia
Background. Allergic rhinitis (AR) is the most prevalent allergic disease globally, particularly within the pediatric population. Its high prevalence and substantial impact on quality of life render it a pressing clinical concern. Notable challenges persist in early diagnosis, comprehension of pathogenetic mechanisms, and optimization of therapeutic strategies, especially in young children. Objective. To present a contemporary review and consensus recommendations from the Association of Pediatric Allergists and Immunologists of Russia (APAIR) on the management of pediatric AR, encompassing pathogenetic mechanisms, risk factors, clinical presentation, diagnostic approaches, and therapeutic modalities. Materials and Methods. This work synthesizes current national and international research, including data from meta-analyses and clinical guidelines, alongside original expert contributions from APAIR members. Results. Experts conceptualize AR as a mixed immune-inflammatory disorder involving the classical IgE-dependent pathway (Type I), cellular responses (Type IV), and epithelial dysfunction (Type V). The significance of risk factors, including genetics, microbiome composition, pollutant exposure, and allergen contact, is underscored. Data on the substantial prevalence of AR are presented, highlighting its underdiagnosis in young children and patients with comorbid conditions such as atopic dermatitis and food allergy. A refined, more clinically applicable definition of AR is proposed. Algorithms for stepwise pharmacotherapy are thoroughly detailed, including the evidence-based use of antihistamines as initial therapy for young children and patients with mild AR, intranasal corticosteroids as the cornerstone of treatment, and fixed intranasal combinations for both baseline and on-demand therapy. A personalized approach based on age (0–18 years) and clinical phenotype is emphasized. APAIR experts underscore the role of allergen-specific immunotherapy (AIT) as the only disease-modifying intervention, in contrast to pharmacotherapy, which primarily provides symptomatic control. Conclusion. Timely diagnosis and appropriate, stepwise therapy for AR in children facilitate symptom control and significantly improve patients’ quality of life. Furthermore, the incorporation of AIT can prevent disease progression, including the development of bronchial asthma. This consensus document aims to assist clinicians in making evidence-based clinical decisions.
- Open Access
- 28 February 2024
- Published by National Medical Research Center for Childrens Health in Russian Pediatric Journal
- Vol. 27 (1) , 28-33
Community-acquired pneumonia in young children living in various climatogeographic zones of the Republic of Dagestan
Introduction. Community-acquired pneumonia (CAP) in early childhood continues to cause significant morbidity and remains one of the most common serious infections in childhood. Each region of the Russian Federation exhibits specific manifestations of CAP morbidity. Knowledge of CAP etiology is crucial for planning therapeutic and preventive measures. Aim. To determine the etiological and immunological features of CAP in early childhood, residing in various climatogeographical zones of the Republic of Dagestan. Materials and methods. The material includes the results of examination and treatment of CAP 204 young children. living in lowland, foothill and mountain climatogeographical zones of the Republic of Dagestan. The selection criterion was the clinical-radiological diagnosis of CAP, using the classification of clinical forms of bronchopulmonary diseases in children. Results. The study revealed a rise in the incidence of respiratory organ diseases, including CAP, among children in the Republic of Dagestan (RD) over the past 5 years. Among infants under one year, the CAP rate was twice as high. The prevalence can be attributed to the climatogeographical conditions of children’s living environments. Streptococcal infection was also observed to predominate in the ethnostructure of CAP in early childhood across all climatogeographical zones. Streptococcus pneumoniae (48.1%) was more frequently isolated in all climatogeographical zones, while Staphylococcus aureus (13.3%) dominated in the mid-mountain zone. In mild pneumonia, cellular immunity components, represented by reduced CD3, CD4, CD25, CD71, react primarily. Disease exacerbation leads to depletion of CD8, CD16, CD20. Severe pneumonia triggers the involvement of humoral immunity, leading to changes in clinical blood analysis — leukocytosis and an increase in mature and immature forms of neutrophils. The levels of IL-1, IL-6, IL-8 in blood serum increase depending on the area of inflammation and the CAP severity. In observed children with focal-draining and segmental CAP, their levels significantly increased. For empirical antibacterial therapy of CAP, recommendations include amoxicillin, protected ampicillins, third-generation cephalosporins, macrolides, and vancomycin in mono- or combination therapy. Conclusion. The conducted research highlights the need for managing ethnological monitoring with antibiotic sensitivity testing of infectious agents causing CAP in children.
- 28 February 2024
- Published by National Medical Research Center for Childrens Health in Russian Pediatric Journal
- Vol. 27 (1) , 28-33
Open AccessCommunity-acquired pneumonia in young children living in various climatogeographic zones of the Republic of Dagestan
Introduction. Community-acquired pneumonia (CAP) in early childhood continues to cause significant morbidity and remains one of the most common serious infections in childhood. Each region of the Russian Federation exhibits specific manifestations of CAP morbidity. Knowledge of CAP etiology is crucial for planning therapeutic and preventive measures. Aim. To determine the etiological and immunological features of CAP in early childhood, residing in various climatogeographical zones of the Republic of Dagestan. Materials and methods. The material includes the results of examination and treatment of CAP 204 young children. living in lowland, foothill and mountain climatogeographical zones of the Republic of Dagestan. The selection criterion was the clinical-radiological diagnosis of CAP, using the classification of clinical forms of bronchopulmonary diseases in children. Results. The study revealed a rise in the incidence of respiratory organ diseases, including CAP, among children in the Republic of Dagestan (RD) over the past 5 years. Among infants under one year, the CAP rate was twice as high. The prevalence can be attributed to the climatogeographical conditions of children’s living environments. Streptococcal infection was also observed to predominate in the ethnostructure of CAP in early childhood across all climatogeographical zones. Streptococcus pneumoniae (48.1%) was more frequently isolated in all climatogeographical zones, while Staphylococcus aureus (13.3%) dominated in the mid-mountain zone. In mild pneumonia, cellular immunity components, represented by reduced CD3, CD4, CD25, CD71, react primarily. Disease exacerbation leads to depletion of CD8, CD16, CD20. Severe pneumonia triggers the involvement of humoral immunity, leading to changes in clinical blood analysis — leukocytosis and an increase in mature and immature forms of neutrophils. The levels of IL-1, IL-6, IL-8 in blood serum increase depending on the area of inflammation and the CAP severity. In observed children with focal-draining and segmental CAP, their levels significantly increased. For empirical antibacterial therapy of CAP, recommendations include amoxicillin, protected ampicillins, third-generation cephalosporins, macrolides, and vancomycin in mono- or combination therapy. Conclusion. The conducted research highlights the need for managing ethnological monitoring with antibiotic sensitivity testing of infectious agents causing CAP in children.
- Open Access
- 7 January 2024
- Published by Association of Pediatric Allergologists and Immunologists of Russia in Allergology and Immunology in Paediatrics
- No. 4,p. 5-30
Allergen-specific immunotherapy in children. Consensus document of the Association of Pediatric Allergologists and Immunologists of Russia (positional pаper)
The Document contains fundamental provisions regarding allergen specific immunotherapy in children.International clinical recommendations on the methodology were used, adapted for use in real practice.In the absence of international recommendations, the authors present the consensus opinion of the project participants, based on data from clinical studies in this area.At the moment, we bring to your attention a position paper on allergen specific immunotherapy in children, created by experts from the Association of Pediatric Allergologists and Immunologists of Russia (APAIR) based on the 2021 consensus document, with the necessary data updates.
- 7 January 2024
- Published by Association of Pediatric Allergologists and Immunologists of Russia in Allergology and Immunology in Paediatrics
- No. 4,p. 5-30
Open AccessAllergen-specific immunotherapy in children. Consensus document of the Association of Pediatric Allergologists and Immunologists of Russia (positional pаper)
The Document contains fundamental provisions regarding allergen specific immunotherapy in children.International clinical recommendations on the methodology were used, adapted for use in real practice.In the absence of international recommendations, the authors present the consensus opinion of the project participants, based on data from clinical studies in this area.At the moment, we bring to your attention a position paper on allergen specific immunotherapy in children, created by experts from the Association of Pediatric Allergologists and Immunologists of Russia (APAIR) based on the 2021 consensus document, with the necessary data updates.
- Open Access
- 27 December 2023
- Published by National Medical Research Center for Childrens Health in Russian Pediatric Journal
- Vol. 26 (6) , 455-458
Primary immunodeficiency in the 9-year child
Primary immunodeficiency conditions are a heterogeneous group of disorders caused by defects in various parts of the immune system, manifested in the form of recurrent infectious and autoimmune diseases of varying severity. The authors describe own clinical observation to determine the principles of diagnosis and treatment of primary immunodeficiency in children in modern conditions. The average age of diagnosis of an immunodeficiency condition has been established to be best over 30 days, but often this time increases to several years. The data of the enrolment of primary immunodeficiency states of the Republic of Dagestan on the diagnosis and permanent replacement therapy of immunodeficiency states is also presented.
- 27 December 2023
- Published by National Medical Research Center for Childrens Health in Russian Pediatric Journal
- Vol. 26 (6) , 455-458
Open AccessPrimary immunodeficiency in the 9-year child
Primary immunodeficiency conditions are a heterogeneous group of disorders caused by defects in various parts of the immune system, manifested in the form of recurrent infectious and autoimmune diseases of varying severity. The authors describe own clinical observation to determine the principles of diagnosis and treatment of primary immunodeficiency in children in modern conditions. The average age of diagnosis of an immunodeficiency condition has been established to be best over 30 days, but often this time increases to several years. The data of the enrolment of primary immunodeficiency states of the Republic of Dagestan on the diagnosis and permanent replacement therapy of immunodeficiency states is also presented.